AIM: To determine whether gastric and enteric Helicobacter species are associated with pancreatic cancer. METHODS: Patients with exocrine pancreatic cancer (n = 40), neuroendocrine cancer (n = 14), multiple endocrine neoplasia type 1 (n = 8), and chronic pancreatitis (n = 5) were studied. Other benign pancreatic diseases (n = 10) and specimens of normal pancreas (n = 7) were included as controls. Pancreatic tissue specimens were analyzed by Helicobacter-specific PCR-assay and products were characterized by denaturing gradient electrophoresis and DNA-sequencing. From a subset of the pancreatic cancer patients, gastric and/or duodenal tissue as well as gallbladder and ductus choledochus tissue were analyzed. Gallbladder and choledochus samples were included as controls. Stomach and duodenum samples were investigated to analyze whether a gastric helicobacter might disseminate to the pancreas in pancreatic cancer patients. Pancreatic specimens were analyzed by Bacteroides-specific PCR for detecting the translocation of indigenous gut microbes to the diseased pancreas. RESULTS: Helicobacter DNA was detected in pancreas (tumor and/or surrounding tissue) of 75% of patients with exocrine cancer, 57% of patients with neuroendocrine cancer, 38% of patients with multiple endocrine neoplasia, and 60% of patients with chronic pancreatitis. All samples from other benign pancreatic diseases and normal pancreas were negative. Thirty-three percent of the patients were helicobacter-positive in gastroduodenal specimens. Surprisingly, H. bilis was identified in 60% of the positive gastroduodenal samples. All gallbladder and ductus choledochus specimens were negative for helicobacter. Bacteroides PCR-assay was negative for all pancreatic samples. CONCLUSION: Helicobacter DNA commonly detected in pancreatic cancer suggests a possible role of the emerging pathogens in the development of chronic pancreatitis and pancreatic cancer.
AIM: To determine whether gastric and enteric Helicobacter species are associated with pancreatic cancer. METHODS:Patients with exocrine pancreatic cancer (n = 40), neuroendocrine cancer (n = 14), multiple endocrine neoplasia type 1 (n = 8), and chronic pancreatitis (n = 5) were studied. Other benign pancreatic diseases (n = 10) and specimens of normal pancreas (n = 7) were included as controls. Pancreatic tissue specimens were analyzed by Helicobacter-specific PCR-assay and products were characterized by denaturing gradient electrophoresis and DNA-sequencing. From a subset of the pancreatic cancerpatients, gastric and/or duodenal tissue as well as gallbladder and ductus choledochus tissue were analyzed. Gallbladder and choledochus samples were included as controls. Stomach and duodenum samples were investigated to analyze whether a gastric helicobacter might disseminate to the pancreas in pancreatic cancerpatients. Pancreatic specimens were analyzed by Bacteroides-specific PCR for detecting the translocation of indigenous gut microbes to the diseased pancreas. RESULTS: Helicobacter DNA was detected in pancreas (tumor and/or surrounding tissue) of 75% of patients with exocrine cancer, 57% of patients with neuroendocrine cancer, 38% of patients with multiple endocrine neoplasia, and 60% of patients with chronic pancreatitis. All samples from other benign pancreatic diseases and normal pancreas were negative. Thirty-three percent of the patients were helicobacter-positive in gastroduodenal specimens. Surprisingly, H. bilis was identified in 60% of the positive gastroduodenal samples. All gallbladder and ductus choledochus specimens were negative for helicobacter. Bacteroides PCR-assay was negative for all pancreatic samples. CONCLUSION: Helicobacter DNA commonly detected in pancreatic cancer suggests a possible role of the emerging pathogens in the development of chronic pancreatitis and pancreatic cancer.
Authors: Milutin Bulajic; Patrick Maisonneuve; Wulf Schneider-Brachert; Petra Müller; Udo Reischl; Bojan Stimec; Norbert Lehn; Albert B Lowenfels; Matthias Löhr Journal: Cancer Date: 2002-11-01 Impact factor: 6.860
Authors: Cornelis Verhoef; Raymond G Pot; Rob A de Man; Pieter E Zondervan; Ernst J Kuipers; Jan N IJzermans; Johannes G Kusters Journal: Eur J Gastroenterol Hepatol Date: 2003-11 Impact factor: 2.566
Authors: Waleed Abu Al-Soud; Mads Bennedsen; Stephen L W On; Ibn-Sina Ouis; Peter Vandamme; Hans-Olof Nilsson; Åsa Ljungh; Torkel Wadström Journal: J Med Microbiol Date: 2003-09 Impact factor: 2.472
Authors: Maria P Dore; Antonia R Sepulveda; Antonietta Pedroni; Giuseppe Realdi; Giuseppe Delitala Journal: Intern Emerg Med Date: 2008-02-09 Impact factor: 3.397
Authors: James J Farrell; Lei Zhang; Hui Zhou; David Chia; David Elashoff; David Akin; Bruce J Paster; Kaumudi Joshipura; David T W Wong Journal: Gut Date: 2011-10-12 Impact factor: 23.059
Authors: Paola Pisani; Mark T Whary; Ingrid Nilsson; Supannee Sriamporn; Torkel Wadström; James G Fox; Asa Ljungh; David Forman Journal: Clin Vaccine Immunol Date: 2008-07-02
Authors: Adeyinka O Laiyemo; Farin Kamangar; Pamela M Marcus; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes; Rachael Z Stolzenberg-Solomon Journal: Cancer Epidemiol Date: 2009-10-01 Impact factor: 2.984
Authors: Erika Del Castillo; Richard Meier; Mei Chung; Devin C Koestler; Tsute Chen; Bruce J Paster; Kevin P Charpentier; Karl T Kelsey; Jacques Izard; Dominique S Michaud Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-10-29 Impact factor: 4.254